CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells

Immunotherapies with chimeric antigen receptor (CAR) T cells and checkpoint inhibitors (including antibodies that antagonize programmed cell death protein 1 [PD-1]) have both opened new avenues for cancer treatment, but the clinical potential of combined disruption of inhibitory checkpoints and CAR...

Descripción completa

Detalles Bibliográficos
Autores principales: Rupp, Levi J., Schumann, Kathrin, Roybal, Kole T., Gate, Rachel E., Ye, Chun J., Lim, Wendell A., Marson, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428439/
https://www.ncbi.nlm.nih.gov/pubmed/28389661
http://dx.doi.org/10.1038/s41598-017-00462-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428439/
https://www.ncbi.nlm.nih.gov/pubmed/28389661
http://dx.doi.org/10.1038/s41598-017-00462-8

Ejemplares similares